Upstream Bio (NASDAQ:UPB) Trading Up 11.2% – Should You Buy?

Shares of Upstream Bio, Inc. (NASDAQ:UPB) traded up 11.2% on Wednesday . The stock traded as high as $9.29 and last traded at $9.40. 77,905 shares were traded during trading, a decline of 94% from the average session volume of 1,337,421 shares. The stock had previously closed at $8.45.

Analysts Set New Price Targets

UPB has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Lifesci Capital assumed coverage on Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target for the company. Finally, Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Upstream Bio currently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Upstream Bio Stock Up 12.1%

The stock has a market cap of $511.76 million, a price-to-earnings ratio of -5.05 and a beta of 2.96. The firm’s 50 day moving average is $17.26 and its two-hundred day moving average is $21.59.

Institutional Trading of Upstream Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bain Capital Life Sciences Investors LLC boosted its position in Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after purchasing an additional 144,216 shares during the period. Integral Health Asset Management LLC acquired a new stake in Upstream Bio in the third quarter worth $10,816,000. Geode Capital Management LLC lifted its stake in Upstream Bio by 57.5% in the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after buying an additional 235,958 shares during the last quarter. Norges Bank bought a new stake in Upstream Bio in the second quarter valued at $10,650,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Upstream Bio during the second quarter valued at $89,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.